Fontas E, et al. - Researchers performed a prospective, randomized, double-blind, placebo-controlled study in France to assess the effectiveness of gliadin‐protected SOD (GP‐SOD), associated with narrowband ultraviolet B (NB‐UVB), for treating vitiligo. Individuals with non‐segmental vitiligo affecting more than 5% of the total body surface were involved. The participants were given gliadin‐protected SOD (GP‐SOD; 1g/d for 12 weeks followed by 0.5g/d for 12 weeks) or placebo in conjunction with twice-weekly NB‐UVB sessions. In total, 50 patients were involved. In the treatment of vitiligo patients, the use of GP‐SOD seems to be a useful add‐on to phototherapy. There have been no reports of related side effects.